| human | Q5 |
| P269 | IdRef ID | 083799672 |
| P496 | ORCID iD | 0000-0002-4899-7116 |
| P2038 | ResearchGate profile ID | Brian-Ott-3 |
| P214 | VIAF ID | 173534813 |
| P106 | occupation | neurologist | Q783906 |
| P21 | sex or gender | male | Q6581097 |
| Q47549851 | 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery |
| Q92925473 | A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease |
| Q53388257 | A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease. |
| Q48593200 | A SPECT imaging study of MRI white matter hyperintensity in patients with degenerative dementia |
| Q36719734 | A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure |
| Q36879027 | A longitudinal study of drivers with Alzheimer disease. |
| Q92665211 | A pilot study of repetitive transcranial magnetic stimulation in primary progressive aphasia |
| Q37360299 | A review of telephone-administered screening tests for dementia diagnosis |
| Q35796451 | A single-photon emission computed tomography imaging study of driving impairment in patients with Alzheimer's disease |
| Q53254470 | A survey of voter participation by cognitively impaired elderly patients |
| Q37351242 | A telephone intervention for dementia caregivers: background, design, and baseline characteristics. |
| Q35048302 | Amnestic behavior in dementia: symptoms to assist in early detection and diagnosis |
| Q48785549 | Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals |
| Q98950312 | Anticholinergic/Sedative Drug Burden and Subjective Cognitive Decline in Older Adults at Risk of Alzheimer's Disease |
| Q36687782 | Anxiety of Alzheimer's disease patients before and after a standardized on-road driving test. |
| Q48377387 | Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease |
| Q48785857 | Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study |
| Q37230930 | Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? |
| Q36733293 | Assessment of cognition in early dementia |
| Q50706909 | Assessment of driving-related skills prediction of unsafe driving in older adults in the office setting. |
| Q35844926 | Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans |
| Q36791964 | Association of fish oil supplement use with preservation of brain volume and cognitive function |
| Q48626449 | Behavioral problems as predictors of functional abilities of vascular dementia patients |
| Q43061423 | Benzene inhalation by parts washers: new estimates based on measures of occupational exposure to solvent coaromatics |
| Q58729492 | Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines |
| Q48469397 | Brain SPECT scanning |
| Q37653343 | Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. |
| Q34802970 | Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease |
| Q34175825 | Cerebral atrophy, apolipoprotein E ɛ4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment |
| Q36322415 | Clinical Utility of the Trail-Making Test as a Predictor of Driving Performance in Older Adults |
| Q44757303 | Clinical correlates of cognitive decline in vascular dementia |
| Q38599299 | Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. |
| Q35796414 | Clinician assessment of the driving competence of patients with dementia |
| Q45854537 | Clock Drawing as a Screen for Impaired Driving in Aging and Dementia: Is It Worth the Time? |
| Q37498749 | Clock drawing as a screen for impaired driving in aging and dementia: is it worth the time? |
| Q94545438 | Cognition After Lowering LDL-Cholesterol With Evolocumab |
| Q34185647 | Cognition and behavior in patients with Alzheimer's disease |
| Q47946231 | Cognitive Function in a Randomized Trial of Evolocumab |
| Q52012356 | Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. |
| Q49244103 | Cognitive and functional status in two subtypes of vascular dementia. |
| Q74661173 | Cognitive decline among female estrogen users in nursing homes |
| Q71722889 | Cognitive effects of flumazenil in patients with Alzheimer's disease |
| Q35676397 | Comparing caregiver and clinician predictions of fitness to drive in people with Alzheimer's disease |
| Q33609573 | Complementary and alternative medicines for Alzheimer's disease |
| Q35796403 | Computerized maze navigation and on-road performance by drivers with dementia |
| Q52002058 | Considering phasic alerting in Alzheimer's disease: comment on Tales et al. (2006). |
| Q36227616 | Creating a driving profile for older adults using GPS devices and naturalistic driving methodology |
| Q46904301 | Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin bac |
| Q58795031 | Detection of Lane-Change Events in Naturalistic Driving Videos |
| Q53414697 | Detection of Risky Driving Behaviors in the Naturalistic Environment in Healthy Older Adults and Mild Alzheimer's Disease. |
| Q47240379 | Differential Contributions of Selective Attention and Sensory Integration to Driving Performance in Healthy Aging and Alzheimer's Disease |
| Q50574596 | Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease. |
| Q90626679 | Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval |
| Q51816918 | Dissociable Effects of Aging and Mild Cognitive Impairment on Bottom-Up Audiovisual Integration. |
| Q28085282 | Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials |
| Q38988517 | Driving Errors in Persons with Dementia |
| Q89912379 | Driving Safety of Cognitively-Impaired Drivers Based on Near Collisions in Naturalistic Driving |
| Q80980321 | Driving and dementia: a review of the literature |
| Q73309017 | Driving and dementia: the medical perspective |
| Q33163707 | Driving policy after seizures and unexplained syncope: a practice guide for RI physicians |
| Q40783051 | Driving policy issues and the physician |
| Q37189562 | Driving safety among older adults |
| Q35796534 | Driving scenes test of the Neuropsychological Assessment Battery (NAB) and on-road driving performance in aging and very mild dementia |
| Q34085402 | Dual-task conditions modulate the efficiency of selective attention mechanisms in Alzheimer's disease |
| Q91675483 | Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways |
| Q45276463 | Effect of cognitive status on self-regulatory driving behavior in older adults: an assessment of naturalistic driving using in-car video recordings |
| Q45340352 | Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. |
| Q35786376 | Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease |
| Q102066059 | Evaluation of Naturalistic Driving Behavior Using In-Vehicle Monitoring Technology in Preclinical and Early Alzheimer's Disease |
| Q98779130 | Evaluation of the Driving Safety of Visually Impaired Bioptic Drivers Based on Critical Events in Naturalistic Driving |
| Q53180212 | Exacerbation of parkinsonism by tacrine |
| Q57707793 | Excessive daytime sleepiness and on-road driving performance in patients with Parkinson's disease |
| Q48833728 | Executive function and magnetic resonance imaging subcortical hyperintensities in vascular dementia |
| Q51905854 | Factor structure of patient and caregiver ratings on the dementia quality of life instrument. |
| Q51034827 | Gender differences in the behavioral manifestations of Alzheimer's disease. |
| Q64785492 | Gender differences in the frequency and treatment of behavior problems in Parkinson's disease |
| Q53232965 | Gender differences in the treatment of behavior problems in Alzheimer's disease. SAGE Study Group. Systemic Assessment of Geriatric drug use via Epidemiology. |
| Q96225557 | Heart Failure and Fitness-to-Drive: Do We Know When to Say When? |
| Q33760359 | How does dementia affect driving in older patients? |
| Q71312722 | Impaired awareness of deficits in Alzheimer disease |
| Q96580821 | Impaired integration of object feature knowledge in amnestic mild cognitive impairment |
| Q35626445 | Impaired knowledge of driving laws is associated with recommended driving cessation in cognitively impaired older adults |
| Q53228216 | Insight and cognitive impairment: effects on quality-of-life reports from mild cognitive impairment and Alzheimer's disease patients. |
| Q51895401 | Integrating patient and informant reports on the Cornell-Brown Quality-of-Life Scale. |
| Q51941460 | Interactions between phasic alerting and spatial orienting: effects of normal aging and Alzheimer's disease. |
| Q40398418 | Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? |
| Q52021010 | Lateralized cortical perfusion in women with Alzheimer's disease. |
| Q71148563 | Leuprolide treatment of sexual aggression in a patient with Dementia and the Klüver-Bucy syndrome |
| Q35796529 | Maze test performance and reported driving ability in early dementia |
| Q34786487 | Medical treatment of Alzheimer's disease: past, present, and future. |
| Q51914500 | Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. |
| Q51977342 | Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. |
| Q50650887 | Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults. |
| Q44991045 | Mortality in donepezil-treated patients |
| Q36600279 | Naturalistic validation of an on-road driving test of older drivers |
| Q44678425 | Neuroimaging correlates of dementia rating scale performance at baseline and 12-month follow-up among patients with vascular dementia |
| Q35796497 | Neuropsychological deficits associated with driving performance in Parkinson's and Alzheimer's disease |
| Q51977193 | Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. |
| Q40524296 | Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease |
| Q43647376 | Performance on the Hooper Visual Organizational Test in patients diagnosed with subcortical vascular dementia: relation to naming performance. |
| Q48931994 | Performance on the Mattis Dementia Rating Scale in patients with vascular dementia: relationships to neuroimaging findings |
| Q35574995 | Pharmacotherapy of dementia with Lewy bodies |
| Q92976441 | Phasic alerting enhances spatial orienting in healthy aging but not in mild cognitive impairment |
| Q42748728 | Preclinical Alzheimer's disease and longitudinal driving decline |
| Q85505331 | Predicting functional impairments in cognitively impaired older adults using the Minnesota Cognitive Acuity Screen |
| Q35585582 | Predicting road test performance in drivers with dementia |
| Q33576220 | Predicting road test performance in drivers with stroke |
| Q38892045 | Prediction of Cognitive and Functional Decline Using the Telephone-Administered Minnesota Cognitive Acuity Screen. |
| Q35796477 | Prediction of on-road driving performance in patients with early Alzheimer's disease |
| Q91514282 | Preliminary Investigation on the Association between Depressive Symptoms and Driving Performance in Heart Failure |
| Q45204289 | Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia. |
| Q53331073 | Premature Alzheimer disease was not due to trauma: molecular biology revises diagnosis 15 years after patient's autopsy. |
| Q46752668 | Preoperative cognitive impairment and psychological distress in hospitalized elderly hip fracture patients |
| Q45263413 | Progressive morphometric and cognitive changes in vascular dementia |
| Q35162966 | Prototype learning and dissociable categorization systems in Alzheimer's disease |
| Q35014112 | Psychosocial telephone intervention for dementia caregivers: A randomized, controlled trial. |
| Q24797104 | Quality of Life measures for dementia |
| Q53201951 | Quantitative assessment of movement in Alzheimer's disease. |
| Q33904728 | Randomized Trial of the Family Intervention: Telephone Tracking-Caregiver for Dementia Caregivers: Use of Community and Healthcare Resources |
| Q35779028 | Reduced Physical Fitness in Patients With Heart Failure as a Possible Risk Factor for Impaired Driving Performance |
| Q44703081 | Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients |
| Q42557906 | Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. |
| Q36399996 | Road test and naturalistic driving performance in healthy and cognitively impaired older adults: does environment matter? |
| Q50657593 | Screening for Mild Cognitive Impairment Using the Dementia Rating Scale-2. |
| Q64867926 | Should risperidone be used in Parkinson's disease? |
| Q60619377 | Single Photon Emission Computed Tomography, Magnetic Resonance Imaging Hyperintensity, and Cognitive Impairments in Patients With Vascular Dementia |
| Q53352657 | Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. |
| Q49678393 | Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease |
| Q48299438 | Telephone-based Minnesota Cognitive Acuity Screen predicts time to institutionalization and homecare |
| Q53248603 | The Cornell-Brown Scale for Quality of Life in dementia. |
| Q48512777 | The Cornell-Brown scale for quality of life in dementia: Spanish adaptation and validation |
| Q88681553 | The Modified Telephone-Administered Minnesota Cognitive Acuity Screen for Mild Cognitive Impairment |
| Q51958180 | The global deterioration scale: relationships to neuropsychological performance and activities of daily living in patients with vascular dementia. |
| Q44255822 | The long and winding road Toward Alzheimer prevention FDA offers new guidance on developing drugs for early-stage AD; seeks input |
| Q51938645 | The neuropsychological profile of vascular cognitive impairment--no dementia: comparisons to patients at risk for cerebrovascular disease and vascular dementia. |
| Q34041499 | The older adult driver with cognitive impairment: "It's a very frustrating life". |
| Q48484164 | The relationship of subcortical MRI hyperintensities and brain volume to cognitive function in vascular dementia |
| Q38521868 | Unilateral Greater Occipital Nerve Compression Causing Scalp Numbness |
| Q50980473 | Use of the telephone-administered Minnesota Cognitive Acuity Screen to detect mild cognitive impairment. |
| Q88878635 | Using the A/T/N Framework to Examine Driving in Preclinical AD |
| Q50799356 | Utility of the cognitive difficulties scale and association with objective test performance. |
| Q39687333 | Validity of informant reports about AD and MCI patients' memory |
| Q73338438 | Vascular dementia |
| Q37653129 | Video Feedback Intervention to Enhance the Safety of Older Drivers With Cognitive Impairment |
| Q36562673 | Visual and cognitive predictors of driving safety in Parkinson's disease patients |
Search more.